DV 281

Drug Profile

DV 281

Alternative Names: DV281

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lung cancer

Most Recent Events

  • 09 Mar 2017 Dynavax plans clinical trials of DV 281 (Inhalation) in combination with a PD-1 inhibitor for Non-small cell lung cancer in 2017 (Dynavax Technologies website, March 2017)
  • 05 Jan 2017 Dynavax plans a phase I trial for Lung cancer in the second quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top